4D Molecular Therapeutics
- Market cap
- 675.08M
- P/E (TTM)i
- -4.65
- P/Bi
- 1.66
- EPSi
- -2.42
- Div yieldi
- 0.00%
- 52W posi
- 53%
Anonymous reader poll. Unscientific, not investment advice.
About 4D Molecular Therapeutics
4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.
- Founded
- 2013
- CEO
- Mr. David Kirn, M.D.
- Employees
- 196
- Headquarters
- Emeryville, California, United States of America
- Fiscal year end
- 12-31
- Website
- 4dmoleculartherapeutics.com
Company profile
- Exchange
- US
- Symbol
- FDMT
- Market-cap rank
- #3519
- Listing date
- 2020-12-11
- Market cap
- 675.08M
- Float cap
- 519.29M
- Shares out
- 55.24M
- Float shares
- 42.50M
Sectors & themes
Quote time 2026-10-08 09:59:57 · For reference only, not investment advice and not tailored to your situation.